Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-12-30
2010-12-21
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387700, C530S388100, C530S388800, C424S130100, C424S133100, C424S134100, C424S138100, C435S007100
Reexamination Certificate
active
07855276
ABSTRACT:
The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.
REFERENCES:
patent: 5472693 (1995-12-01), Gourlie et al.
patent: 5851526 (1998-12-01), Welt et al.
patent: 6020153 (2000-02-01), Hardman et al.
patent: 6333405 (2001-12-01), Anderson et al.
patent: 6417337 (2002-07-01), Anderson et al.
patent: 7355008 (2008-04-01), Stavenhagen et al.
patent: 2002/0052479 (2002-05-01), Anderson et al.
patent: 2003/0039649 (2003-02-01), Foote
patent: WO00/26394 (2000-05-01), None
patent: WO03/002607 (2003-01-01), None
patent: WO2004/006955 (2004-01-01), None
patent: WO2004/022717 (2004-03-01), None
Adams et al., “Generating improved single-chain Fv molecules tumor targeting,”Journal of Immunological Methods, 231:249-260 (1999).
Osbourn et al., “Generation of a panel of related human scFv antibodies with high affinities for human CEA,”Immunotechnology, 2:181-196 (1996).
Caldas et al., “Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen,”Protein Eng., 13(5):353-360, 2000.
Caldas et al., “Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen,”Mol. Immunol., 39(15):941-952, 2003.
De Pascalis et al., “Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody,”J. Immunol., 169(6):3076-3084, 2002.
Folli et al., “Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen,”Proc. Natl. Acad. Sci. USA, 89(17):7973-7977, 1992.
Gonzales et al., “Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues,”Mol. Immunol., 40(6):337-349, 2003.
Gonzales et al., “SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity,”Mol. Immunol., 41(9):863-872, 2004.
Kashmiri et al., “Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49,”Hybridoma, 14(5):461-473, 1995.
Kashmiri et al., “Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49,”Crit. Rev. Oncol. Hematol., 38:3-16, 2001.
Kashmiri et al., Chapter 21, pp. 361-376,Methods in Molecular Biology, vol. 248:Antibody Engineering: Methods and Protocols, Ed.: B.K.C. Lo, Humana Press, Tolowa, NJ, 2004.
Kass et al., “Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer,”Cancer Res., 62(17):5049-5057, 2002.
Muraro et al., “Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues,”Cancer Res., 45(11 Pt 2):5769-5780, 1985.
Ohuchi et al., “Differential expression of carcinoembryonic antigen in early gastric adenocarcinomas versus benign gastric lesions defined by monoclonal antibodies reactive with restricted antigen epitopes,”Cancer Res., 47(13):3565-3571, 1987.
Padlan et al., “Identification of specificity-determining residues in antibodies,”FASEB J., 9(1):133-139, 1995.
Raben et al., “Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene,”Gene Ther., 3(7):567-580, 1996.
Ravindranath et al., “Does human melanoma express carcinoembryonic antigen,” 20(5A):3083-3092, 2000 (abstract only).
Raynor et al., “Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells,”BMC Cancer, 2:14, 2002.
Robbins et al., “Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas,”Int. J. Cancer, 53(6):892-897, 1993 (abstract only).
Rosok et al., “A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab,”J. Biol. Chem., 271(37):22611-22618, 1996.
Siler et al., “Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1),”Biotechnol. Ther., 4(3-4):163-181, 1993 (abstract only).
Tamura et al., “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only,”J. Immunol., 164(3):1432-1441, 2000.
Tan et al., “″SuperhumanizedΔ antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28,”J. Immunol., 169(2):1119-1125, 2002.
Wilkinson et al., “Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors,”Proc. Natl. Acad. Sci. USA, 98(18):10256-10260, 2001.
Yan et al., “Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells,”J. Biol. Chem., 272(44):27902-27907, 1997.
Yu et al., “Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics,”J. Clin. Oncol., 14(6):1798-1809, 1996.
Kashmiri, legal representative Rafia Mehdi
Kasmiri Syed
Padlan Eduardo A.
Schlom Jeffrey
Gussow Anne M.
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
LandOfFree
Framework residue substituted humanized COL-1 antibodies and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Framework residue substituted humanized COL-1 antibodies and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Framework residue substituted humanized COL-1 antibodies and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4185856